Phase 1 Granuloma Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Chronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT05463133
Recruiting
Phase 1Phase 2
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
X-Linked Chronic Granulomatous Disease
Ensoma15 enrolled9 locationsNCT06876363
Recruiting
Phase 1
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
InfectionChronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)25 enrolled1 locationNCT05189925
Recruiting
Phase 1Phase 2
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease
National Institute of Allergy and Infectious Diseases (NIAID)10 enrolled1 locationNCT06325709
Recruiting
Phase 1Phase 2
Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis
Chronic Granulomatous Disease-associated Colitis
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT05333471
Recruiting
Phase 1Phase 2
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Systemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSjogren's Syndrome+6 more
Essen Biotech75 enrolled1 locationNCT06350110
Recruiting
Phase 1
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Rheumatoid ArthritisPemphigus VulgarisSystemic Lupus Erythematosus+1 more
IRIS Research and Development, LLC30 enrolled1 locationNCT06581562